TG Therapeutics(US:TGTX) Globenewswire·2025-07-30 11:30Core Viewpoint - TG Therapeutics, Inc. will hold a conference call on August 4, 2025, to discuss its second-quarter financial results and provide a business outlook for the remainder of 2025 [1]. Company Overview - TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases [4]. - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) [4]. - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS who have active disease in Europe and the United Kingdom [4]. Conference Call Details - The conference call will be hosted by Michael S. Weiss, Chairman and CEO, and will take place at 8:30 AM ET [1]. - Participants can join the call by dialing specific numbers for U.S. and international callers, and a live webcast will be available on the company's website [2]. - An audio recording of the conference call will be accessible for replay for 30 days after the event [2][3].